Deerfield Management Company, L.P. (Series C) Eye Point Pharmaceuticals, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 14, 2024	BUY	$8.16 - $22.89 $2.43 Million - $6.83 Million	298,196 Added 51.45%	877,790 $7.64 Million
Q1 2024 May 15, 2024	BUY	$19.93 - $29.71 $11.6 Million - $17.2 Million	579,594 New	579,594 $12 Million

Others Institutions Holding EYPT

# of Institutions

150

Shares Held

58M

Call Options Held

177K

Put Options Held

263K

Cormorant Asset Management, LP Boston, MA

8.33M
Shares

$87.3 Million
4.66% of portfolio
Suvretta Capital Management, LLC New York, NY

5.18M
Shares

$54.3 Million
1.63% of portfolio
Franklin Resources Inc San Mateo, CA

4.01M
Shares

$42.1 Million
0.01% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.79M
Shares

$39.8 Million
0.06% of portfolio
Black Rock Inc. New York, NY

3.76M
Shares

$39.5 Million
0.0% of portfolio

View Full List

About EyePoint Pharmaceuticals, Inc.

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $357M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

More about EYPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account